Skip to content
HomeLatest newsGlobal Trial Finder: Why it just got easier to enroll in a Janssen clinical study
Global Trial Finder

Global Trial Finder: Why it just got easier to enroll in a Janssen clinical study

More than 35,000 of the world’s most dedicated scientists and innovators work for the Janssen Pharmaceutical Companies of Johnson & Johnson, helping to research and develop new ways to treat and prevent some of the world’s most complex diseases.

But there’s another key component that’s necessary when it comes to finding new therapies for conditions like Alzheimer’s disease, rheumatoid arthritis and cancer: you.

Janssen Research & Development routinely conducts clinical trials to evaluate investigational medications and treatment regimens, and that requires the participation of hundreds—sometimes even thousands—of volunteers.

But finding enough willing and qualified participants can often be a challenge.

Enter the Janssen Global Trial Finder, an easy-to-use database of clinical trials that are currently accepting new participants for a variety of diseases. People interested in enrolling in a study can search by medical condition and geographic location.

“We understand both the health-related reasons people seek to participate in clinical trials, and the motivation to help others who may face similar experiences in the future,” says Bert Hartog, Ph.D., Director and Clinical Trial Innovation Lead at Janssen. “So we wanted to offer a resource for easily accessing our clinical trials globally—a resource that can enable us to continue to advance innovative medicines to treat, prevent, intercept and cure some of the most complex diseases of our time.”

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.